X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8270) 8270
Book Review (1254) 1254
Publication (515) 515
Newsletter (474) 474
Conference Proceeding (91) 91
Newspaper Article (27) 27
Book Chapter (21) 21
Dissertation (9) 9
Magazine Article (9) 9
Trade Publication Article (6) 6
Web Resource (3) 3
Transcript (2) 2
Paper (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
capecitabine (7404) 7404
index medicus (5874) 5874
humans (5845) 5845
oncology (4723) 4723
female (4138) 4138
deoxycytidine - analogs & derivatives (3358) 3358
middle aged (3325) 3325
chemotherapy (3240) 3240
aged (3178) 3178
fluorouracil - analogs & derivatives (2988) 2988
male (2856) 2856
antineoplastic combined chemotherapy protocols - therapeutic use (2720) 2720
cancer (2621) 2621
adult (2533) 2533
deoxycytidine - administration & dosage (2258) 2258
fluorouracil - administration & dosage (2191) 2191
treatment outcome (1917) 1917
care and treatment (1533) 1533
oxaliplatin (1400) 1400
breast neoplasms - drug therapy (1357) 1357
colorectal cancer (1322) 1322
fluorouracil (1314) 1314
breast cancer (1282) 1282
5-fluorouracil (1268) 1268
antineoplastic combined chemotherapy protocols - adverse effects (1265) 1265
metastasis (1227) 1227
research (1207) 1207
therapy (1158) 1158
deoxycytidine - adverse effects (1132) 1132
aged, 80 and over (1113) 1113
deoxycytidine - therapeutic use (1098) 1098
colorectal neoplasms - drug therapy (1054) 1054
disease-free survival (1035) 1035
fluorouracil - adverse effects (1028) 1028
fluorouracil - therapeutic use (957) 957
organoplatinum compounds - administration & dosage (926) 926
pharmacology & pharmacy (926) 926
trial (926) 926
neoplasm staging (925) 925
survival (909) 909
medicine & public health (902) 902
breast neoplasms - pathology (887) 887
neoplasm metastasis (858) 858
bevacizumab (832) 832
antimetabolites, antineoplastic - therapeutic use (808) 808
drug therapy (803) 803
antineoplastic agents - therapeutic use (748) 748
prognosis (745) 745
combination (730) 730
surgery (728) 728
retrospective studies (711) 711
antineoplastic combined chemotherapy protocols - administration & dosage (708) 708
clinical trials (707) 707
radiotherapy (697) 697
carcinoma (679) 679
hematology, oncology and palliative medicine (678) 678
drug administration schedule (670) 670
analysis (656) 656
leucovorin (650) 650
1st-line treatment (646) 646
cisplatin (643) 643
survival rate (627) 627
adenocarcinoma - drug therapy (626) 626
antimetabolites, antineoplastic - adverse effects (621) 621
colorectal neoplasms - pathology (616) 616
health aspects (616) 616
phase-ii (611) 611
oncology, experimental (604) 604
irinotecan (591) 591
docetaxel (584) 584
antineoplastic agents (576) 576
antimetabolites, antineoplastic - administration & dosage (575) 575
stomach neoplasms - drug therapy (575) 575
gemcitabine (567) 567
tumors (563) 563
survival analysis (560) 560
toxicity (546) 546
antimitotic agents (544) 544
chemotherapy, adjuvant (541) 541
trastuzumab (539) 539
adenocarcinoma (536) 536
capecitabine - administration & dosage (526) 526
administration, oral (524) 524
cancer patients (523) 523
camptothecin - analogs & derivatives (511) 511
phase-ii trial (504) 504
phase-iii trial (502) 502
paclitaxel (496) 496
cancer research (479) 479
oral capecitabine (474) 474
patients (473) 473
chemoradiotherapy (470) 470
metastatic colorectal-cancer (470) 470
cancer therapies (468) 468
gastric cancer (458) 458
colorectal-cancer (456) 456
efficacy (453) 453
stomach cancer (447) 447
combined modality therapy (446) 446
follow-up studies (439) 439
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8253) 8253
Japanese (168) 168
German (101) 101
French (93) 93
Chinese (65) 65
Spanish (35) 35
Korean (26) 26
Italian (25) 25
Russian (23) 23
Polish (16) 16
Dutch (11) 11
Turkish (11) 11
Czech (10) 10
Hungarian (7) 7
Portuguese (4) 4
Danish (3) 3
Romanian (2) 2
Finnish (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dermatologic Therapy, ISSN 1396-0296, 05/2019, Volume 32, Issue 3, pp. e12853 - n/a
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2018, Volume 103, Issue 2, pp. 210 - 216
Journal Article
12/2010
Capecitabine is an oral chemotherapeutic agent converted to 5 flourouracil (5-FU). Neurotoxicity associated with the medication encompasses both central and... 
neurotoxicity | Capecitabine | cancer
Web Resource
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e384 - e386
Currently, treatment of small bowel adenocarcinoma (SBA) mirrors that of colorectal cancer (CRC). Recent genomic data have demonstrated SBA to be a genetically... 
CAPECITABINE | ONCOLOGY | PHASE-II
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 08/2018, Volume 18, Issue 4, pp. 289 - 297
We report the results from a phase I study of buparlisib, an oral pan-class I phosphotidyinositol-3-kinase inhibitor, combined with capecitabine in patients... 
Buparlisib | Breast cancer | Phase I | PI3K | Capecitabine | PLUS CAPECITABINE | TRASTUZUMAB | ONCOLOGY | PATHWAY | MUTATIONS | BKM120 | Capecitabine - administration & dosage | Breast Neoplasms - secondary | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | Adult | Female | Morpholines - adverse effects | Capecitabine - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Aminopyridines - toxicity | Drug Administration Schedule | Morpholines - administration & dosage | Capecitabine - toxicity | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - toxicity | Phosphatidylinositol 3-Kinases - genetics | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Antimetabolites, Antineoplastic - toxicity | Protein Kinase Inhibitors - toxicity | Morpholines - toxicity | Morpholines - pharmacokinetics | Mutation | Dosage and administration | Metastasis | Drug therapy, Combination | Drug therapy | Methods | Index Medicus
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 05/2016, Volume 14, Issue 1, pp. 125 - 125
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2017, Volume 161, Issue 1, pp. 63 - 72
Journal Article
Journal Article
10/2011
A 59-year-old man with adenocarcinoma of stomach was prescribed capecitabine as adjuvant chemotherapy. After two cycles of therapy, patient developed... 
hyperpigmentation | Capecitabine | hand-foot syndrome
Web Resource
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article